Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities
Launched by NOVO NORDISK A/S · Oct 6, 2020
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- • Male or female, age above or equal to 12 years at the time of signing informed consent.
- • Haemophilia A (any severity), needing prophylactic therapy (with the usual recommended doses).
- • Decision to treat with turoctocog alfa, made by the treating Physician and the subject/Legally Acceptable Representative (LAR) based on local label before and independently from the decision to include the subject in this study.
- Exclusion Criteria:
- • Previous participation in this study, defined as previously signed informed consent;
- • Presence of other coagulation disorders;
- • Presence of any inhibitor;
- • Mental problems, poor compliance, linguistic barriers or other conditions which can impede the understanding of the study aims and the participation to it.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company headquartered in Denmark, specializing in the research, development, manufacturing, and marketing of innovative pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapies. With a strong commitment to improving patient outcomes, Novo Nordisk invests significantly in clinical trials to advance scientific knowledge and develop effective therapies. The company is dedicated to sustainability and ethical practices, striving to deliver high-quality healthcare solutions while addressing the evolving needs of patients worldwide. Through collaboration and innovation, Novo Nordisk aims to lead the way in transforming diabetes and other chronic diseases into manageable conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roma, , Italy
Firenze, , Italy
Bologna, , Italy
Castelfranco Veneto, , Italy
Vicenza, , Italy
Catania, , Italy
Cesena, , Italy
Milano, , Italy
Napoli, , Italy
Milano, Mi, Italy
Patients applied
Trial Officials
Clinical Reporting Anchor and Disclosure 1452
Study Director
Novo Nordisk A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials